{"id":"https://openalex.org/W2152245709","doi":"https://doi.org/10.2174/1567205010666131212110148","title":"A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer\u2019s Disease","display_name":"A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer\u2019s Disease","publication_year":2014,"publication_date":"2014-01-06","ids":{"openalex":"https://openalex.org/W2152245709","doi":"https://doi.org/10.2174/1567205010666131212110148","mag":"2152245709","pmid":"https://pubmed.ncbi.nlm.nih.gov/24359500"},"language":"en","primary_location":{"id":"doi:10.2174/1567205010666131212110148","doi":"https://doi.org/10.2174/1567205010666131212110148","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1567205010666131212110148","pdf_url":null,"source":{"id":"https://openalex.org/S188438558","display_name":"Current Alzheimer Research","issn_l":"1567-2050","issn":["1567-2050","1875-5828"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018686207","display_name":"Richard A. Grove","orcid":"https://orcid.org/0000-0002-5722-4406","observed_orcids":["https://orcid.org/0000-0002-5722-4406"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Grove","raw_affiliation_strings":["GlaxoSmithKline (GSK) US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline (GSK) US","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008537066","display_name":"Conn M. Harrington","orcid":"https://orcid.org/0009-0001-7319-0330","observed_orcids":["https://orcid.org/0009-0001-7319-0330"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Conn Harrington","raw_affiliation_strings":["GlaxoSmithKline (GSK) US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline (GSK) US","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042434545","display_name":"Andreas Mahler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andreas Mahler","raw_affiliation_strings":["Andreas Mahler, Neurozentrum Achim"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Andreas Mahler, Neurozentrum Achim","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036499203","display_name":"I.J.M. Beresford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Isabel Beresford","raw_affiliation_strings":["GlaxoSmithKline (GSK) US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline (GSK) US","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064879007","display_name":"Paul T. Maruff","orcid":"https://orcid.org/0000-0002-6947-9537","observed_orcids":["https://orcid.org/0000-0002-6947-9537"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Maruff","raw_affiliation_strings":["Cogstate Pty Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cogstate Pty Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109073875","display_name":"Martin T. Lowy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Lowy","raw_affiliation_strings":["GlaxoSmithKline (GSK) US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline (GSK) US","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110286618","display_name":"Andrew J. Nicholls","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Nicholls","raw_affiliation_strings":["GlaxoSmithKline (GSK) US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline (GSK) US","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rebecca Boardley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Boardley","raw_affiliation_strings":["GlaxoSmithKline (GSK) US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline (GSK) US","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111468461","display_name":"Ali\u00e9nor Berges","orcid":"https://orcid.org/0000-0002-7078-327X","observed_orcids":["https://orcid.org/0000-0002-7078-327X"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alienor Berges","raw_affiliation_strings":["GlaxoSmithKline (GSK) US"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline (GSK) US","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018958936","display_name":"Pradeep J. Nathan","orcid":"https://orcid.org/0000-0003-0943-5329","observed_orcids":["https://orcid.org/0000-0003-0943-5329"]},"institutions":[{"id":"https://openalex.org/I241749","display_name":"University of Cambridge","ror":"https://ror.org/013meh722","country_code":"GB","type":"education","lineage":["https://openalex.org/I241749"]},{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Pradeep Nathan","raw_affiliation_strings":["GlaxoSmithKline (GSK) US; University of Cambridge"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline (GSK) US; University of Cambridge","institution_ids":["https://openalex.org/I241749","https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073856009","display_name":"Joseph P. Horrigan","orcid":"https://orcid.org/0000-0002-9336-5820","observed_orcids":["https://orcid.org/0000-0002-9336-5820"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Horrigan","raw_affiliation_strings":["Neurosciences Therapeutic Area, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC, 27709, USA. conn.m.harrington@gsk.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurosciences Therapeutic Area, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC, 27709, USA. conn.m.harrington@gsk.com","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":5.582,"has_fulltext":false,"cited_by_count":113,"citation_normalized_percentile":{"value":0.97713244,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"11","issue":"1","first_page":"47","last_page":"58"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.8184000253677368,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.8184000253677368,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.11379999667406082,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.05480000004172325,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/histamine-h3-receptor-antagonists","display_name":"histamine H3 receptor antagonists","score":0.8799999952316284},{"id":"https://openalex.org/keywords/histamine","display_name":"histamine","score":0.5389999747276306},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9649999737739563},{"id":"https://openalex.org/keywords/episodic-memory","display_name":"episodic memory","score":0.8209999799728394},{"id":"https://openalex.org/keywords/executive-function","display_name":"executive function","score":0.9480000138282776},{"id":"https://openalex.org/keywords/working-memory","display_name":"working memory","score":0.9860000014305115},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.7369999885559082},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5669999718666077},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7279999852180481},{"id":"https://openalex.org/keywords/sleep-disturbance","display_name":"sleep disorders","score":0.8100000023841858},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.7250000238418579},{"id":"https://openalex.org/keywords/cogstate","display_name":"CogState","score":0.5759999752044678},{"id":"https://openalex.org/keywords/adas-cog","display_name":"ADAS-Cog","score":0.8650000095367432},{"id":"https://openalex.org/keywords/brain-penetrant-drugs","display_name":"brain-penetrant drugs","score":0.6010000109672546},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.6010000109672546},{"id":"https://openalex.org/keywords/cholinergic-transmission","display_name":"cholinergic neurotransmission","score":0.6489999890327454},{"id":"https://openalex.org/keywords/monoaminergic-neurotransmission","display_name":"monoaminergic neurotransmission","score":0.9480000138282776}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6630404591560364},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5051706433296204},{"id":"https://openalex.org/C2779338893","wikidata":"https://www.wikidata.org/wiki/Q5025484","display_name":"Cambridge Neuropsychological Test Automated Battery","level":5,"score":0.502830445766449},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.49067461490631104},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.48580265045166016},{"id":"https://openalex.org/C88576662","wikidata":"https://www.wikidata.org/wiki/Q18646","display_name":"Episodic memory","level":3,"score":0.464335560798645},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.4299507737159729},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40120935440063477},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.355773389339447},{"id":"https://openalex.org/C21963081","wikidata":"https://www.wikidata.org/wiki/Q11337567","display_name":"Working memory","level":3,"score":0.32617565989494324},{"id":"https://openalex.org/C169900460","wikidata":"https://www.wikidata.org/wiki/Q2200417","display_name":"Cognition","level":2,"score":0.2593187093734741},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.1965366005897522},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.15339168906211853},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.15227264165878296},{"id":"https://openalex.org/C43729271","wikidata":"https://www.wikidata.org/wiki/Q3560550","display_name":"Spatial memory","level":4,"score":0.11113271117210388},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006633","descriptor_name":"Histamine Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008570","descriptor_name":"Memory, Short-Term","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009483","descriptor_name":"Neuropsychological Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018697","descriptor_name":"Nootropic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018697","descriptor_name":"Nootropic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D055118","descriptor_name":"Medication Adherence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056344","descriptor_name":"Executive Function","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D061212","descriptor_name":"Memory, Episodic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/1567205010666131212110148","doi":"https://doi.org/10.2174/1567205010666131212110148","is_oa":false,"landing_page_url":"https://doi.org/10.2174/1567205010666131212110148","pdf_url":null,"source":{"id":"https://openalex.org/S188438558","display_name":"Current Alzheimer Research","issn_l":"1567-2050","issn":["1567-2050","1875-5828"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer Research","raw_type":"journal-article"},{"id":"pmid:24359500","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24359500","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2044573535","https://openalex.org/W2169963222","https://openalex.org/W2130900903","https://openalex.org/W1902663605","https://openalex.org/W2004525253","https://openalex.org/W2051330983","https://openalex.org/W2168379833","https://openalex.org/W2000217206","https://openalex.org/W1549535539","https://openalex.org/W2042502927"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Histaminergic":[1],"H3":[2,30,289],"receptors":[3],"may":[4],"play":[5],"a":[6,25,77,89,97],"role":[7],"in":[8,88,108,191,217,231,274,302],"modulating":[9],"cholinergic":[10],"and":[11,21,111,178,188,208,282,296],"monoaminergic":[12],"neurotransmission.":[13],"This":[14],"Phase":[15],"II":[16],"study":[17],"evaluated":[18],"the":[19,118,158,185,192,205,258],"efficacy":[20,102],"safety":[22,219,281],"of":[23,249,257],"GSK239512,":[24,222],"highly":[26],"potent,":[27],"brain":[28],"penetrant":[29],"receptor":[31],"antagonist":[32],"as":[33,262],"monotherapy":[34],"treatment":[35,166],"for":[36],"subjects":[37,56,197],"with":[38,57,169,175,233,304],"mild-to-moderate":[39,305],"probable":[40],"Alzheimer's":[41,159],"disease":[42],"(AD).":[43],"METHODS:":[44],"In":[45],"this":[46,275],"16-week,":[47],"double-blind,":[48],"randomized,":[49],"parallel":[50],"group":[51],"study,":[52],"196":[53],"currently":[54],"untreated":[55],"mild-tomoderate":[58],"AD":[59],"(Mini":[60],"Mental":[61],"State":[62],"Examination":[63],"[MMSE]":[64],"16-24)":[65],"received":[66],"GSK239512":[67,82,131,165,203,269,277],"(n=97);":[68],"or":[69,153,246],"placebo":[70,79],"(n=99)":[71],"administered":[72],"orally":[73],"each":[74],"morning.":[75],"After":[76],"two-week":[78],"run-in":[80],"period":[81,195],"was":[83,167],"up-titrated":[84],"over":[85],"4":[86],"weeks":[87],"flexible":[90],"manner":[91],"(10-20-40-80":[92],"microgram":[93],"[\u00b5g])":[94],"followed":[95],"by":[96],"12-week":[98],"Maintenance":[99],"Phase.":[100],"Co-primary":[101],"endpoints":[103,264],"were":[104,147,198,212,240,253],"change":[105],"from":[106,117],"baseline":[107],"Episodic":[109,133,229],"Memory":[110,114,134,230,245],"Executive":[112,243],"Function/Working":[113,244],"composite":[115],"scores":[116],"CogState":[119],"neuropsychological":[120],"test":[121],"battery":[122],"(NTB)":[123],"at":[124,135,204,223,292],"Week":[125,136],"16.":[126],"RESULTS:":[127],"Compared":[128],"to":[129,171,181,202,226,271],"placebo,":[130],"improved":[132,228],"16":[137],"(Effect":[138],"Size":[139],"[ES]":[140],"=0.35;":[141],"p=0.0495).":[142],"No":[143,251],"statistically":[144],"significant":[145],"differences":[146],"observed":[148,241,254],"on":[149,154,242,255,299],"other":[150,218,247],"cognitive":[151,300],"domains":[152,248],"clinical":[155,259],"measures":[156,260],"including":[157],"Disease":[160],"Assessment":[161],"Scale-Cognitive":[162],"Subscale":[163],"(ADASCog).":[164],"associated":[168],"mild":[170],"moderate":[172,235],"adverse":[173],"events":[174,179],"headache,":[176],"dizziness":[177],"related":[180],"sleep":[182],"disturbances":[183],"being":[184,200],"most":[186],"common":[187],"more":[189],"pronounced":[190],"early":[193],"titration":[194],"when":[196],"first":[199],"exposed":[201],"lower":[206],"10\u00b5g":[207],"20\u00b5g":[209],"doses.":[210],"There":[211],"no":[213,238],"clinically":[214],"relevant":[215],"changes":[216,252],"parameters.":[220],"CONCLUSION:":[221],"doses":[224],"up":[225],"80\u00b5g/day,":[227],"patients":[232,303],"mildto-":[234],"AD.":[236,306],"However,":[237],"improvements":[239],"cognition.":[250],"any":[256],"included":[261],"secondary":[263],"(including":[265],"ADAS-Cog)":[266],"indicating":[267],"that":[268,288],"failed":[270],"show":[272],"benefit":[273],"population.":[276],"had":[278],"an":[279],"acceptable":[280],"tolerability":[283],"profile.":[284],"These":[285],"findings":[286],"suggest":[287],"antagonists":[290],"may,":[291],"most,":[293],"have":[294],"modest":[295],"selective":[297],"effects":[298],"function":[301]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":12},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":21},{"year":2015,"cited_by_count":12},{"year":2014,"cited_by_count":4}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}